INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1]. Financial Performance - On August 7, 2025, Sensus reported a GAAP earnings-per-share of -$0.06 for Q2 2025, missing estimates by $0.09 [3]. - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3]. - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some growth in recurring revenue from Fair Deal Agreements [3]. Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4].